To maintain chronic BCR activation, approximately 20% of ABC DLBCL tumors exhibit somatic mutations in the co-receptors CD79B and less commonly CD79A (Figure 2b) [67]. This evidence concerns the gene CD79B and diffuse large B-cell lymphoma.